Matthew Clary, MD
Ophthalmology · Columbia, SCNPI 1538345004
Payments from drug & device makers
Across 781 payments — averaging $158.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$88K
- Sight Sciences, Inc.$19K
- Alcon Research LLC$4K
- Alcon$4K
- Sun Pharmaceutical Industries Inc.$2K
- Ocular Therapeutix, Inc.$731
- plus $6K from 28 others
What the payments were for
- Consulting fees$3,0503%
- Speaking & faculty fees$93,95079%
- Travel & lodging$6,1805%
- Food & beverage$15,80213%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 198 | $87,881 |
| Sight Sciences, Inc. | 43 | $19,331 |
| Alcon Research LLC | 2 | $4,400 |
| Alcon | 115 | $3,559 |
| Sun Pharmaceutical Industries Inc. | 118 | $1,651 |
| Ocular Therapeutix, Inc. | 41 | $731 |
| NEW World Medical,inc. | 12 | $674 |
| Novartis | 26 | $600 |
| Bausch & Lomb Americas Inc. | 31 | $578 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $529 |
| Mallinckrodt Hospital Products Inc. | 19 | $465 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 32 | $447 |
| Kala Pharmaceuticals, Inc. | 29 | $381 |
| Tarsus Pharmaceuticals, Inc. | 13 | $307 |
| Oyster Point Pharma, Inc. | 15 | $285 |
| Rayner Intraocular Lenses Limited | 11 | $224 |
| Glaukos Corporation | 5 | $208 |
| Omeros Corporation | 12 | $182 |
| Amgen(2 entities) | 9 | $169 |
| Biotissue Holdings Inc. | 3 | $160 |
| Thea Pharma Inc. | 4 | $124 |
| Harrow Eye, LLC | 6 | $107 |
| Dompe US, Inc. | 4 | $100 |
| Aerie Pharmaceuticals, Inc. | 5 | $92 |
| Optos, Inc. | 1 | $65 |
| Shire North American Group Inc | 4 | $53 |
| Lensar, Inc. | 1 | $43 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Rxsight Inc | 1 | $26 |
| Ivantis, Inc | 2 | $24 |
| Iridex Corporation | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Maculogix, Inc. | 1 | $14 |
| Apellis Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$84,747
- OMNI(R) SURGICAL SYSTEM (US)$18,766
- SION SURGICAL INSTRUMENT$6,643
- AcrySof IQ PanOptix UV IOL$1,050
- AcrySof IQ VIVITY$1,050
- XEN$400
- Clareon$278
- XEN GLAUCOMA TREATMENT SYSTEM$272
- LUMIGAN$125
- CATALYS SYSTEM$125
- CEQUA$123
- AcrySof$113
- Kahook Dual Blade$107
- Clearpath$107
- Ahmed Glaucoma Valve$107
- Streamline$107
- Tecnis Multifocal Family of 1-piece IOLS$101
- AcrySof IQ VIVITY IOL$101
How this compares
$123,491 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 170 | $80,493 |
| RestasisCyclosporine | 50 | $67,935 |
| VyzultaLatanoprostene Bunod | 50 | $23,754 |
| Cyclosporine | 31 | $19,377 |
| XiidraLifitegrast | 16 | $17,800 |
| IlevroNepafenac | 48 | $17,744 |
| ProlensaBromfenac Sodium | 47 | $16,582 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 78 | $15,789 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $14,744 |
| CequaCyclosporine | 14 | $14,171 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $12,796 |
| Alphagan PBrimonidine Tartrate | 35 | $11,097 |
| Travoprost | 32 | $7,676 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $6,807 |
| Brimonidine Tartrate | 111 | $5,531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $87,881 | $172,321282 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $578 | $41,55466 claims |
| NovartisIlevro | $600 | $17,74448 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $447 | $16,58247 claims |
| AlconSimbrinza | $3,559 | $14,74468 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,651 | $14,17114 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $92 | $6,80718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Columbia
- Willard HarmsColumbia$14K
- Robert HuffColumbia$13K
- Stephen CrossColumbia$11K
- Ryan MercerColumbia$9K
- John WellsWest Columbia$7.1M
- William ClarkWest Columbia$6.2M
- Daniel AlfaroCharleston$4.6M
- Kerry SolomonMt Pleasant$4.6M
- Eric JablonCharleston$1.2M
- George WaringMt Pleasant$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.